These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 36727075)
1. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Peng X; Gong C; Zhang W; Zhou A Front Oncol; 2022; 12():1091088. PubMed ID: 36727075 [TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
3. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802 [TBL] [Abstract][Full Text] [Related]
4. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Lin ZF; Qin LX; Chen JH Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935 [TBL] [Abstract][Full Text] [Related]
6. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Chen Y; Hu H; Yuan X; Fan X; Zhang C Front Immunol; 2022; 13():896752. PubMed ID: 35757756 [TBL] [Abstract][Full Text] [Related]
7. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Gok Yavuz B; Hasanov E; Lee SS; Mohamed YI; Curran MA; Koay EJ; Cristini V; Kaseb AO J Hepatocell Carcinoma; 2021; 8():1195-1207. PubMed ID: 34595140 [TBL] [Abstract][Full Text] [Related]
8. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A Front Oncol; 2018; 8():269. PubMed ID: 30057891 [TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapies for advanced hepatocellular carcinoma. Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485 [TBL] [Abstract][Full Text] [Related]
11. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482 [TBL] [Abstract][Full Text] [Related]
13. Recent developments with immunotherapy for hepatocellular carcinoma. Waidmann O Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439 [TBL] [Abstract][Full Text] [Related]
14. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Rizzo A; Ricci AD; Brandi G Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621 [TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma. Jeng LB; Wang J; Teng CF J Cancer; 2024; 15(2):484-493. PubMed ID: 38169551 [TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Pelizzaro F; Farinati F; Trevisani F Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189643 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for hepatocellular carcinoma. Childs A; Aidoo-Micah G; Maini MK; Meyer T JHEP Rep; 2024 Oct; 6(10):101130. PubMed ID: 39308986 [TBL] [Abstract][Full Text] [Related]
19. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533 [TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W Front Immunol; 2020; 11():1037. PubMed ID: 32547550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]